Media Summary: Encouraging trial data is instilling both confidence and capital back into the psychedelic Dr. Steve Levine, Chief Patient Officer at In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ...
Compass Pathways Eyes Fda Approval For Psilocybin Depression Drug - Detailed Analysis & Overview
Encouraging trial data is instilling both confidence and capital back into the psychedelic Dr. Steve Levine, Chief Patient Officer at In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ... Professor David Hellerstein is a Professor of Clinical Psychiatry and Principal Investigator on If one or two psychedelic sessions can produce measurable improvements in treatment-resistant What if the future of mental health didn't rely on daily pills or endless therapy sessions? One biotech startup believes the answer ...
In this deep-dive, we analyze the landmark Phase 3 clinical data from The psychedelic industry was shocked by the In this episode of Divergent States, we sit down with Kabir Nath, CEO of
